Incyte Reports Baricitinib NDA Filing for Rheumatoid Arthritis

Incyte Reports Baricitinib NDA Filing for Rheumatoid Arthritis

We remind investors that in 2009, Incyte and Lilly had entered into an exclusive worldwide license and collaboration agreement to develop and commercialize baricitinib and certain follow-on compounds, for the treatment of patients with inflammatory and …

(Visited 1 times, 1 visits today)
5
Like
Save

Comments

Comments are disabled for this post.